Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ).
Hangzhou Tigermed Consulting Co., Ltd. has scheduled a board meeting for March 30, 2026, to review and approve the annual results for the year ended December 31, 2025, for the company and its subsidiaries, and to authorize their release. The board will also consider whether to recommend a final dividend, a step that could affect shareholder returns and signal management’s confidence in the company’s financial performance.
The announcement also reconfirms the current composition of Tigermed’s board, listing four executive directors and three independent non-executive directors. This governance disclosure underscores the mix of management and independent oversight in place as the company heads into its next results cycle and potential capital return decisions.
The most recent analyst rating on (HK:3347) stock is a Buy with a HK$61.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.
More about Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. is a China-incorporated joint stock company listed in Hong Kong, operating in the pharmaceutical and healthcare services sector as a contract research organization. It provides clinical research and related consulting services to biopharmaceutical companies, focusing on drug development support and regulatory-driven outsourcing in domestic and international markets.
Average Trading Volume: 2,136,666
Technical Sentiment Signal: Hold
Current Market Cap: HK$46.01B
For a thorough assessment of 3347 stock, go to TipRanks’ Stock Analysis page.